Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. 1994

H Mochizuki, and H Imai, and K Endo, and K Yokomizo, and Y Murata, and N Hattori, and Y Mizuno
Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.

The mechanism of abnormal iron accumulation in the substantia nigra (SN) pars compacta of patients with Parkinson's disease (PD) is unknown. To explore this question, we made a hemiparkinsonism model in monkeys by injecting 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) into the caudate or putamen on one side, and compared iron content in the SN and other basal ganglia structures by histochemistry. The injected side, especially the SN pars compacta, showed a marked increase in iron staining. Our study indicates that an injury to the nigrostriatal system by MPTP injection can induce iron accumulation in the SN.

UI MeSH Term Description Entries
D007501 Iron A metallic element with atomic symbol Fe, atomic number 26, and atomic weight 55.85. It is an essential constituent of HEMOGLOBINS; CYTOCHROMES; and IRON-BINDING PROTEINS. It plays a role in cellular redox reactions and in the transport of OXYGEN. Iron-56,Iron 56
D008252 Macaca fascicularis A species of the genus MACACA which typically lives near the coast in tidal creeks and mangrove swamps primarily on the islands of the Malay peninsula. Burmese Long-Tailed Macaque,Crab-Eating Monkey,Cynomolgus Monkey,M. f. aurea,M. fascicularis,Macaca fascicularis aurea,Monkey, Crab-Eating,Monkey, Cynomolgus,Crab-Eating Macaque,Burmese Long Tailed Macaque,Crab Eating Macaque,Crab Eating Monkey,Crab-Eating Macaques,Crab-Eating Monkeys,Cynomolgus Monkeys,Long-Tailed Macaque, Burmese,Macaque, Burmese Long-Tailed,Macaque, Crab-Eating,Monkey, Crab Eating
D008297 Male Males
D008845 Microinjections The injection of very small amounts of fluid, often with the aid of a microscope and microsyringes. Microinjection
D010302 Parkinson Disease, Secondary Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42) Atherosclerotic Parkinsonism,Secondary Parkinsonism,Symptomatic Parkinson Disease,Parkinson Disease, Secondary Vascular,Parkinson Disease, Symptomatic,Parkinsonism, Secondary,Parkinsonism, Symptomatic,Secondary Vascular Parkinson Disease,Parkinsonism, Atherosclerotic,Secondary Parkinson Disease,Symptomatic Parkinsonism
D002421 Caudate Nucleus Elongated gray mass of the neostriatum located adjacent to the lateral ventricle of the brain. Caudatus,Nucleus Caudatus,Caudatus, Nucleus,Nucleus, Caudate
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001479 Basal Ganglia Large subcortical nuclear masses derived from the telencephalon and located in the basal regions of the cerebral hemispheres. Basal Nuclei,Ganglia, Basal,Basal Nuclear Complex,Ganglion, Basal,Basal Nuclear Complices,Nuclear Complex, Basal,Nuclei, Basal
D013378 Substantia Nigra The black substance in the ventral midbrain or the nucleus of cells containing the black substance. These cells produce DOPAMINE, an important neurotransmitter in regulation of the sensorimotor system and mood. The dark colored MELANIN is a by-product of dopamine synthesis. Nigra, Substantia,Nigras, Substantia,Substantia Nigras
D015632 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease. MPTP,N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine

Related Publications

H Mochizuki, and H Imai, and K Endo, and K Yokomizo, and Y Murata, and N Hattori, and Y Mizuno
February 1992, Zhonghua shen jing jing shen ke za zhi = Chinese journal of neurology and psychiatry,
H Mochizuki, and H Imai, and K Endo, and K Yokomizo, and Y Murata, and N Hattori, and Y Mizuno
February 1996, Neuroscience letters,
H Mochizuki, and H Imai, and K Endo, and K Yokomizo, and Y Murata, and N Hattori, and Y Mizuno
December 1985, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
H Mochizuki, and H Imai, and K Endo, and K Yokomizo, and Y Murata, and N Hattori, and Y Mizuno
February 2009, Journal of neuroscience research,
H Mochizuki, and H Imai, and K Endo, and K Yokomizo, and Y Murata, and N Hattori, and Y Mizuno
May 1989, Journal of the neurological sciences,
H Mochizuki, and H Imai, and K Endo, and K Yokomizo, and Y Murata, and N Hattori, and Y Mizuno
February 1987, Brain research,
H Mochizuki, and H Imai, and K Endo, and K Yokomizo, and Y Murata, and N Hattori, and Y Mizuno
October 1997, Brain research,
H Mochizuki, and H Imai, and K Endo, and K Yokomizo, and Y Murata, and N Hattori, and Y Mizuno
October 1995, Glia,
H Mochizuki, and H Imai, and K Endo, and K Yokomizo, and Y Murata, and N Hattori, and Y Mizuno
March 1990, Research communications in chemical pathology and pharmacology,
H Mochizuki, and H Imai, and K Endo, and K Yokomizo, and Y Murata, and N Hattori, and Y Mizuno
February 2013, Neuropathology and applied neurobiology,
Copied contents to your clipboard!